Brainstorm Cell Therapeutics (BCLI) Getting Somewhat Positive Media Coverage, Report Finds
Media stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.3962701916795 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Brainstorm Cell Therapeutics (BCLI) Lowered to Sell at ValuEngine (americanbankingnews.com)
- BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech … – PR Newswire (press release) (prnewswire.com)
- BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase (finance.yahoo.com)
- Brainstorm Cell Therapeutics (BCLI) versus The Competition Head-To-Head Review (americanbankingnews.com)
- -$0.09 Earnings Per Share Expected for Brainstorm Cell Therapeutics Inc (BCLI) This Quarter (americanbankingnews.com)
BCLI has been the subject of several analyst reports. ValuEngine downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th.
Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) opened at $3.19 on Monday. Brainstorm Cell Therapeutics has a 12-month low of $2.48 and a 12-month high of $5.18. The stock has a market cap of $60.11, a P/E ratio of -10.29 and a beta of 1.47.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the business posted ($0.09) earnings per share. equities analysts anticipate that Brainstorm Cell Therapeutics will post -0.37 earnings per share for the current fiscal year.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.